Actavis Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Forest Laboratories Senior Notes
PR Newswire - Thu Jun 12, 5:16PM CDT
Actavis plc (NYSE: ACT) today announced that Forest Laboratories, Inc. (NYSE: FRX) has received valid consents (the "Requisite Consents"
Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
Business Wire - Thu Jun 12, 4:00PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the "Requisite Consents"
2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering.
Consent Expiry Extensions, Collaborations, Grants, Conference Presentations, and FDA Approvals - Analyst Notes on Forest Laboratories, Intuitive Surgical, Horizon Pharma, Cubist and BDSI
PR Newswire - Thu Jun 12, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories, Inc. (NYSE: FRX), Intuitive Surgical, Inc. (NASDAQ: ISRG), Horizon Pharma Inc (NASDAQ: HZNP), Cubist Pharmaceuticals Inc (NASDAQ: CBST) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3640-100free.
Arrhythmias - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3k97mr/arrhythmias) has announced the addition of the "Arrhythmias - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Gilead Sciences - Forest Laboratories - Orion - Compugen - SciFluor For more information visit http://www.researchandmarkets.com/research/3k...rrhythmias
Forest Laboratories plans to continue marketing both NAMENDA TABLETS and once-daily NAMENDA XR up to autumn of 2014
M2 - Wed Jun 11, 7:12AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Tuesday that it will continue to market both its NAMENDA (memantine HCl) 5 mg and 10 mg tablets and once-daily NAMENDA XR (memantine HCl) extended-release capsules through to the the autumn of this year.
Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.
Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA(R) TABLETS and Once-Daily NAMENDA XR(R) Into the Fall of 2014
Business Wire - Tue Jun 10, 3:01PM CDT
-- Initiatives to Ensure Robust and Reliable Product Supply Progressing--
Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.
2014 Report on the International Pain Management Drugs Market - Forecasts to 2018
M2 - Tue Jun 10, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zh6gc/global_pain) has announced the addition of the "2014 Report on the International Pain Management Drugs Market - Forecasts to 2018" report to their offering. The analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Pain Management Drugs market has also been witnessing intense competition among vendors. However, the increase in generic competition could pose a challenge to the growth of this market. The report, 2014 Report on the International Pain Management Drugs Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pain Management Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Category 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - Eli Lilly and Co. - Endo Health Solutions Inc. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Pfizer Inc. - Purdue Pharma L.P. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/7z...lobal_pain
Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations"
Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company"
Clinical Study Results, Data Presentations, DMF Submissions, and Acquisition Agreements - Analyst Notes on Forest Laboratories, Incyte, Illumina, INSYS Therapeutics and AMRI
PR Newswire - Thu Jun 05, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), Incyte Corporation (NASDAQ: INCY), Illumina Inc. (NASDAQ: ILMN), INSYS Therapeutics, Inc. (NASDAQ: INSY) and Albany Molecular Research Inc. (NASDAQ: AMRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3391-100free.
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
Active Stocks Technical Coverage -- Research on Forest Laboratories, NII Holdings, Endo Intl., and Aramark
PR Newswire - Mon Jun 02, 6:40AM CDT
The trading session on Friday, May 30, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,717.17, up 0.11% and the NASDAQ Composite closed at 4,242.62, down 0.13%. The S&P 500 finished the day 0.18% higher at 1,923.57. During the trading session, eight out of ten sectors finished on a positive note. Investor-Edge has initiated coverage on the following equities: Forest Laboratories Inc. (NYSE: FRX), NII Holdings Inc. (NASDAQ: NIHD), Endo International PLC (NASDAQ: ENDP) and Aramark (NYSE: ARMK). Free technical research on FRX, NIHD, ENDP and ARMK can be downloaded upon signing up at:
Anti-Depressants: The Secret to Preventing Alzheimer's?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat May 31, 3:52PM CDT
The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories under the brand name Celexa, as a potential way to help slow down the development of...
Forest Laboratories, Inc. Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
Business Wire - Fri May 30, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet. In the study, the combination of nebivolol and valsartan met its primary and key secondary endpoints, demonstrating statistically significant reductions from baseline in diastolic and systolic blood pressure vs. both nebivolol alone and valsartan alone at 8 weeks in patients with hypertension.
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics
PR Newswire - Tue May 27, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.
Research and Markets: Global Antibacterial Drugs Market Research Report 2014: Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols
Business Wire - Tue May 27, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pdgs5q/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering.